- VBI Vaccines ( NASDAQ: VBIV ) and Agenus ( NASDAQ: AGEN ) will evaluate a combination of the former's VBI-1901 and the latter's balstilimab as a combination treatment for glioblastoma .
- VBI-1901 is a cancer vaccine immunotherapeutic, while balstilimab is anti-PD-1 monoclonal antibody.
- A phase 2 study, expected to begin around the end of the year, will examine the combination in patients following primary tumor resection and radiotherapy.
- Check out why Seeking Alpha contributor William Meyers is bullish on Agenus ( AGEN ).
For further details see:
VBI Vaccines, Agenus to examine VBI-1901 + balstilimab combo for glioblastoma